Efficacy and Safety of Longyizhengqi Granule in Treatment of Mild COVID-19 Patients Caused by SARS-CoV-2 Omicron Variant: A Prospective Study.

Miao WangJin ShiKepei ZhangJie HongXinwei PengYu TianWei LuKe LiZengliang WangFeng LiZhijie ZhangGuojiang Mei

Published in: Infection and drug resistance (2023)

Longyizhengqi granule might be a promising drug for the treatment of mild COVID-19, and it might be beneficial to effectively shorten the negative transition time of nucleic acid, the total days of hospitalization, and increase the changes of Ct values. Long-term randomized controlled trials with follow-up evaluations are required to confirm its long-term efficacy.

Keyphrases

sars cov
nucleic acid
randomized controlled trial
coronavirus disease
respiratory syndrome coronavirus
emergency department
computed tomography
study protocol